Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
$25.49
$0.08(0.31%)
At close: 4:00 PM EST
$25.49
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$18.35 - $39.92
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$315.65M
Enterprise Value$498.29M
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)$131.91M
Price to Earnings (P/E)34.2
Beta1.25
Next Earnings
Mar 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding12,383,103
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)3.75
Price to Sales (P/S)10.79
P/FCF Ratio-22.33
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue10.58
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda47.81
Forecast
1Y Price Target
$64.50Price Target Upside153.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition And CollaborationThe acquisition of Generation Bio represents another opportunity for future royalties and milestones, especially through its collaboration with Moderna and the underlying ctLNP siRNA delivery technology.
Partnered Assets And CreativityXOMA's creativity in driving both the number of partnered assets and its ability to bring cash in on a non-dilutive basis continues to impress.
Royalty Revenue And Pipeline ProgramsXOMA maintains a Buy rating due to its existing royalty revenue base and additional partnered pipeline programs.
Bears Say
Cash Burn And Financial ChallengesCash burn and long development timelines ultimately led to the acquisition, as Generation Bio could not get ahead of its cash burn despite ending with $89.5 million in cash.
Trial FailuresRezolute Bio's Phase 3 trial with ersodetug did not meet its primary or secondary endpoints.
Uncertainty And Revenue ImpactShare weakness reflecting removal of a near term revenue driver from P&L is a key consideration.
Xoma News
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $18.35 and its highest was $39.92 in the past 12 months.
What is Xoma Corp’s market cap?
Xoma Corp’s market cap is $315.65M.
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Mar 05, 2026 which is in 69 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on Nov 12, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.74.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -0.07.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 12,383,103 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -2.522%.
Which hedge fund is a major shareholder of Xoma Corp?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xoma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.50 (153.04% Upside)
$64.50 (153.04% Upside)
Hedge Fund Trend
Increased
By 29.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.5%
Last 30 Days ▲ 53.7%
Last 30 Days ▲ 53.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
16.22%
Trailing 12-Months
Asset Growth
-8.15%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Stock 12 Month Forecast
Average Price Target
$64.50
▲(153.04% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
RAPT Therapeutics
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
13.18% Insiders
17.53% Mutual Funds
28.49% Other Institutional Investors
32.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---